A new report from Reuters Events offers guidance for pharmaceutical industry solutions providers looking for fresh insights into marketing strategies during the COVID-19 pandemic. The report offers agencies a four-step strategy for marketing during the pandemic, and includes perspectives from […]
ICER Hosting Series on Drug Pricing During a Pandemic
The Institute for Clinical and Economic Review (ICER) is scheduled to host a three-part series focused on drug pricing during a pandemic. The first session, which will discuss cost-recovery pricing, is set for noon EST July 24. Confirmed speakers include: Afton Cissell, JD, Senior Counsel […]
Report: European Drug Regulatory Network Faces Uncertain, Complex Future
A new strategy produced by European regulators considers future challenges for the European drug regulatory network, The Pink Sheet reports. The plan, per the report, looks to position the regulatory network to endure an uncertain future. To read the report, click here. […]
ICER Outlines Planned Review of High Cholesterol Treatments
The Institute for Clinical and Economic Review (ICER) in a recently-released document outlines its planned review of high cholesterol treatments. ICER's assessment will include Novartis' inclisiran, Esperion Therepeutics' Nexletol and Nexlizet, according to a press release. Comments on the […]
Panel Discusses Provider Prospective on Value-Based Care for mBC
A recent panel discussion on AJMC's Peer Exchange discusses how providers identify value-based care opportunities for metastatic breast cancer. The panel features Drs. William Gradishar and Joyce O'Shaughnessy, Bruce Feinberg, Kelli Davis and Steven Peskin. To listen to the discussion on […]
Evidation Looks to Bolster Platform to Include Virtual Treatment
After generating $45 million in investments, Evidation is looking to expand its virtual research platform to include digital interventions and treatments, FierceBiotech reports. According to the report, the platform already has some 4 million participants in the U.S. "Participation in research […]
Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent a lot of time and considerable care and discussion about how to approach the pricing of this medicine," he said. "At this price it's significantly below the value it […]
ICER President: Remdesivir Price was ‘Responsible’ Decisions
The Institute for Clinical and Economic Review's president, Steven Pearson, says Gilead's decision to price its COVID-19 treatment remdesivir at $3,120 was a "responsible pricing decision based on the evidence we have today." Gilead also plans to offer some federal programs a discounted price of […]
Oncologists Grapple with Supply Shortages Amid Pandemic, Survey Finds
A new survey found that one of oncologists' biggest concerns amid the COVID-19 pandemic is supply shortages, Specialty Pharmacy Continuum reports. The survey by the International Society of Oncology Pharmacy Practitioners (ISOPP) suggests oncologists continue to struggle with drug and personal […]
Cytel Outlines Use of Bayesian Methodologies
A new white paper from Cytel outlines how its statisticians have used Bayesian methodologies in the search for effective COVID-19 treatments. "The sense of urgency incites clinical researchers to invoke innovative trial design approaches to expedite the identification of efficacious interventions […]
ISPOR Offers Short Courses on Medical Devices, Payment Models
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is offering short courses on medical devices and different payment models for drugs and other products. Below are the two intermediate courses: Market Access & Value Assessment of Medical Devices, 10 a.m. EST […]
NPC: ‘Ready, aim, fire’ Mentality Detrimental in Health Care
Having a "ready, aim, fire" mentality can prove harmful when sharing health care information, the National Pharmaceutical Council (NPC) writes in a recent blog post. NPC points to the Institute for Clinical and Economic Review's (ICER) report on COVID-19 treatments, calling it "a prime example of […]
ISPOR-FDA Summit Transitions to Virtual Event
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) announced that the joint ISPOR-FDA Summit 2020, set for Sept. 29, will be a virtual event this year. ISPOR and the FDA Center for Devices and Radiological Health are hosting the one-day event. "Virtual ISPOR-FDA […]
Cytel Offers On-Demand Access to Webinar on Synethic, External Control Arms
A new on-demand webinar from Cytel offers insights into synthetic and external control arms in clinical trials. The webinar features Cytel Real-World Evidence Senior Vice President Kristian Thorlund. Cytel also recently published a new scientific primer on using synthetic control arms in place […]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic fibrosis drug is not "discrimination." Kreis, whose 18-year-old daughter has cystic fibrosis, was referring to how some critics responded to ICER's suggestion […]
ICER to Review Most Significant Drug Price Hikes
The Institute for Clinical and Economic Review (ICER) is set to review whether the most significant drug price increases are evidence-based. ICER on Friday released an updated protocol for the annual assessment. An open input period on the drugs tapped for review began Friday, June 19, and […]
Analysis Finds Clinical Trial Costs are Actually Modest
A new analysis published in BMJ Open suggests that clinical trial costs for new drugs are generally modest, according to a STAT report. The analysis, which looked at 101 drugs approved by the FDA between 2015 and 2017, found the median cost of clinical trials to be roughly $48 million per […]
New Definition of HTA
In a letter to the editor published in Value in Health, Brian O'Rourke, Wija Oortwijn and Tara Schuller offer a new definition of health technology assessment (HTA). The authors define HTA as the following: "HTA is a multidisciplinary process that uses explicit methods to determine the value […]
Report: EMA Considers Big Data Network ‘Priority’
The European Medicines Agency (EMA) says the development of a big data network is a "priority" project, according to a Pink Sheet report. According to the report, the agency's 2019 report offered some insight into plans for a new data network. To read the full report on The Pink Sheet, click […]
ISPOR Europe 2020 Deadline for Abstract Submissions Nears
The abstract submission deadline for ISPOR's upcoming European meeting is July 8. ISPOR 2020 Europe is set to kick off Nov. 14 in Milan, Italy. "At the start of a new decade in the shadow of a global pandemic, the questioning of fundamental conventions around value, risk, rewards, and the role […]
Researchers Support Targeted Population Health Interventions to Boost COVID-19 Outcomes
Health care systems should target population health interventions to patients with existing chronic diseases to bolster COVID-19 outcomes, researchers in a recent opinion piece suggest. "The global response has been to treat COVID-19 as a vertical disease rather than addressing the full ecosystem […]
Where Epidemiologists are Leaning on Kids Returning to School
A recent New York Times Upshot article offers comments from 133 epidemiologists on the matter of children returning to school amid the COVID-19 pandemic. The article expands on a survey by The Times in which it asked more than 500 epidemiologists when they planned to resume 20 common activities. […]
Article: U.S. Should Scrap Specialty Drug Label
The U.S. should abandon the specialty-drug label for high-cost drugs and follow suit with other countries that categorize drugs by their clinical- and cost-effectiveness, the authors of a recent article published in NEJM write. Categorizing all expensive drugs as being specialty drugs, Huseyin […]
ICER to CF Community: ‘We Support Actions to Receive Fair Prices’
The Institute for Clinical and Economic Review (ICER) in a letter to the cystic fibrosis community says it supports fair prices that ensure patient access to key drugs. ICER attempted to reassure the community that its position on Trikafta remained one that stresses the need for price […]
How Can Pharma Best Interact with ICER?
A new report from FirstWord looks at how pharma can best engage with the Institute for Clinical and Economic Review (ICER) as its influence in negotiations continues to increase. The report, "Engaging with ICER: Lessons and Insights for Pharma," includes insight from pharmaceutical industry […]
Using AI, NLP and Data Visualization with RWE to Generate Insights into Care Gaps: Retrospective Cohort Analysis of Fracture Risk in Patients with Osteopenia and Osteoporosis
Sponsored by Veradigm Real world data (RWD) are being used by an increasingly diverse group of stakeholders. As an example, patient advocacy groups are realizing the value they can offer to their communities by partnering with data analysis companies to explore treatment pathways, health […]
Report Suggests COVID-19 Could Cost Insurers up to $547 Billion
A new report from Wakely, commissioned by America's Health Insurance Plans (AHIP), suggests COVID-19 could cost payers between $30 billion and $547 billion through 2021, FierceHealthcare reports. In its report, which is an update to the original report posted in March, Wakely says […]
Optum: 8 Forces That Will Determine the Future
Optum in a recent perspective offers eight main drivers that will determine the course of health care beyond the COVID-19 pandemic. "The Coronavirus (COVID-19) has upended the entire health care landscape — and the danger and breadth of the pandemic has accelerated change to previously unseen […]
Houghton St Press Launches New Journal
Houghton St Press recently launched its 10th journal, The Journal of Health Policy and Economics (JOHPEC). The new peer-reviewed journal will focus on health-related works by London School of Economics health policy students. JOHPEC is accepting submissions for its summer issue. To learn […]
Health Affairs Editor: Institutions Must Use Power to Fight Racism
Health Affairs Editor Alan Weil in a recent blog post says health care institutions must "use their power to fight racism," adding that it is insufficient to only stand against and protest it. Weil's blog post, titled "The Social Determinants of Death," spotlights social determinants of health […]
